AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00555620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Capecitabine is given orally at 1000mg/m\^2 twice a day for 14 days followed by 7 days of drug free period.
Study NCT00555620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Oxaliplatin is given 110mg/m\^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
Study NCT00555620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: sunitinib is given orally 25mg/day for 14 days followed by 7 days of drug free period.
Study NCT05268653 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivatıonal İnterviewing (Treatment Group)
Description: Obese adolescents will be given a 6-session motivational interview.
Study NCT01510951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 811 or Placebo
Description: Single dose subcutaneous administration of AMG 811 or placebo to adult subjects with psoriasis.
Study NCT01510951 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AMG 811 or Placebo
Description: Single dose subcutaneous administration of AMG 811 or placebo to adult subjects with psoriasis.
Study NCT03618251 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: specific MRI sequences
Description: MRI with B 2000 of diffusion weighted imaging and the coefficient of apparent diffusion
Study NCT03751176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab 6 mg/kg will be administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy
Study NCT03751176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan 180 mg/m2 will be administered as IV infusion over 90 min on day 1
Study NCT03751176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 180 mg/m2 will be administered as IV infusion over 90 min on day 1
Study NCT03751176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folinic acid
Description: Folinic acid 200-400 mg/m2 will be administered as IV infusion over 2 hours on day 1
Study NCT03751176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic acid
Description: Folinic acid 200-400 mg/m2 will be administered as IV infusion over 2 hours on day 1
Study NCT03751176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 5-FU will be administered IV 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2
Study NCT03751176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU will be administered IV 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2
Study NCT00858494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyland's Cold 'n Cough 4 Kids
Description: Liquid homeopathic cold remedy, 5 ml by mouth every 4 hours as needed for relief of cold symptoms for up to 10 days
Study NCT02316418 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hairstetics™ anchoring system
Description: Overall, up to 360 prosthetic hair implants will be set in the scalp. The procedure will be performed in accordance with the instructions in the device Instructions for Use. Training and certification of operators by the Sponsor is a prerequisite for use of the study device by the former.~Hair extensions will be attached to the fibers four weeks after the implantation.
Study NCT04308941 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Intraocular pressure
Description: The intraocular pressure will be measured using one of three devices
Study NCT03161561 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: capacity of primary phagocytes
Description: measurement of capacity of primary phagocytes (neutrophils, monocytes and macrophages) isolated from COPD patients' blood or alveolar macrophages isolated from patients' lungs to carry out key host defence functions and compare these to similar cells isolated from age and sex-matched non-smokers or smokers without COPD as controls.
Study NCT03561974 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Humidification
Description: Patients will benefit of humidification and warming of delivered gaz by non-invasive ventilation thanks humidification system.
Study NCT01536496 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood product transfusion based on conventional coagulation tests.
Description: Transfusion of blood products.
Study NCT01536496 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood product transfusion based on rapid thrombelastography (r-TEG) results.
Description: Transfusion of blood products.
Study NCT01191710 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In vitro fertilization
Description: In vitro fertilization procedure with gonadotropin induced follicular ovarian stimulation
Study NCT01191710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In vitro fertilization
Description: In vitro fertilization procedure with gonadotropin induced follicular ovarian stimulation
Study NCT01748786 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Emotion Regulation
Description: 12 on-line modules provide didactic information and practice instructions re: mindfulness meditation for pain and distress
Study NCT01748786 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Health Education
Description: 12 on-line modules that provide information regarding health behaviors, but no information regarding how to put behaviors into practice
Study NCT01861626 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: V0057 - A mg
Description: Single oral administration
Study NCT03646721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1241
Description: \[Part1\] Administration once daily for 28 days; Dose strength for each cohort (Cohort 1, 2 and 3) is planned as 50mg, 100mg and 200mg, respectively.~\[Part2\] Administration once daily for 56 days; Dose strength for each cohort (Cohort 4, 5 and 6) is planned as 25mg, 50mg and 100mg, respectively.~(Dose escalation and dose level decisions for subsequent cohorts will be made via interim dose escalation review meetings.)
Study NCT01861626 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Isotretinoin
Description: Single oral administration
Study NCT03391934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab + FOLFIRI
Description: Cetuximab 400 mg/m2 will be administered in the first dose and 250 mg/m2 will be administered in the next doses every week. Irinotecan will be administered 180 mg/m2 biweekly. Leucovorin will be administered 400 mg/m2 biweekly.Fluorouracil will be administered 400 mg/m2 push, and 2400 mg/m2 as 46-h infusion biweekly.
Study NCT03646721 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: \[Part1\] Administration once daily for 28 days. \[Part2\] Administration once daily for 56 days.
Study NCT03646721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: \[Part2\] Administration of Sitagliptin 100mg once daily for 56 days.
Study NCT03391934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab + FOLFIRI
Description: Cetuximab 400 mg/m2 will be administered in the first dose and 250 mg/m2 will be administered in the next doses every week. Irinotecan will be administered 180 mg/m2 biweekly. Leucovorin will be administered 400 mg/m2 biweekly.Fluorouracil will be administered 400 mg/m2 push, and 2400 mg/m2 as 46-h infusion biweekly.
Study NCT00207311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xenical, Pegasys, Copegus
Description: Xenical 120mg three times daily for 36 weeks or xenical placebo (Arm 1). Pegasys 180 mcg weekly for 48 weeks. Ribavirin daily for 48 weeks.
Study NCT00207311 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Xenicare Program
Description: Xenicare program for 36 weeks.
Study NCT02524171 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moral Reconation Therapy (MRT)
Description: MRT is a group-based cognitive-behavioral intervention to restructure antisocial thinking. Patients will receive two groups per week of this intervention for approximately 12 weeks, in addition to the usual care they receive in the mental health residential rehabilitation treatment program.
Study NCT03133507 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reapprasial Condition
Description: Children in this condition will be instructed to think about how the procedure will help them become adjusted to cold weather.
Study NCT03133507 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reassurance Condition
Description: Children will be reassured by the experimenter .
Study NCT03133507 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distraction Condition
Description: Children in this condition will be instructed to focus their attention on a picture on a computer screen rather than on the pain.
Study NCT00704886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video
Description: video of dementia
Study NCT02781675 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: 3 wk dietary intervention with prescribed menus and \~50% foods provided.
Study NCT02535455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACES Pilot
Description: This pilot will consist of 5 individual sessions and an innovative bi-directional text message component that uses participant-written positive self-statements informed by the intervention content (e.g., self-compassion, positive self-reappraisal and nonjudgmental acceptance).
Study NCT03771092 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SunActive®Fe
Description: SunActive® Fe is a colorless, odorless, tasteless iron fortifier in a powder form. This product is most commonly used to increase the amount of iron in food, beverage, and dietary supplement applications.
Study NCT03771092 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipofer®
Description: Lipofer® is a micronized and microencapsulated source of iron, enhances the bioavailability of iron and does not taste metallic or oxidize unsaturated fats.
Study NCT03771092 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intravenous ferric gluconate
Description: Sodium ferric gluconate complex is an iron replacement product for treatment of iron deficiency anemia. The stable macromolecular complex is negatively charged at alkaline pH with an apparent molecular weight of 289,000 - 440,000 daltons on gel chromatography. It is composed of iron (III) oxide hydrate directly bonded to sucrose with a chelating gluconate function in a molar ratio of two iron molecules to one gluconate.
Study NCT01941615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: faldaprevir
Description: oral doses for 10 days (period B)
Study NCT01941615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgynon®
Description: oral doses for 23 days (period A+B)
Study NCT01941615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127
Description: oral doses for 10 days (period B)
Study NCT00047450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram (Celexa)
Description: Citalopram for 3 months
Study NCT00047450 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 3 months
Study NCT01944059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Theramine (medical food/old drug)
Description: Theramine® is a prescription medical food that is composed of variety of amino acids and/or their precursors.
Study NCT01944059 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (l-alanine)
Description: Theramine like placebo comparator
Study NCT03645629 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: skin test with food at different storage times
Description: Perform skin tests to each foods at 0, 3, 6 months after preparation and compare the results
Study NCT02477644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Tablets, per os, 300 mg twice daily;
Study NCT02477644 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, per os, 300 mg twice daily.
Study NCT00477880 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study NCT03766295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib
Study NCT03766295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT03766295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Study NCT03766295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT03613207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dermal pharmacokinetic measurement
Description: * Each subject will have 9 test sites: 4 on the left thigh, 4 on the right thigh, 1 on the arm~* Each test site receives 2 dOFM probes~* Dosing:~  * 2 test sites: 15 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~ * 2 test sites: 10 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~ * 2 test sites: 5 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~ * 1 test site: 10 mg/cm² Oraqix® gel (2.5% lidocaine, 2.5% prilocaine, Dentsply Pharmaceutical Inc., US/Dentsply DETRY GmbH, Germany)~ * 2 test sites: untreated test site~* ISF sampling: 24 hours post-dose~* Blood sampling: 7 samples post-dose
Study NCT03613207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine and prilocaine cream
Description: lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US) will be applied to 6 test sites per subject
Study NCT02545582 — intervention group
Intervention type: DEVICE
Intervention: VITARIA System
Description: Implantable vagus nerve stimulator
Study NCT03829605 — intervention group
Intervention type: OTHER
Intervention: Measurement of hydrogen sulfide
Description: Hydrogen sulfide will be measured by ELISA and correlated with nitric oxide and hyperglycemia
Study NCT03209271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ringer's Acetate (warm)
Description: Body temperature fluid
Study NCT03209271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Acetate (cold)
Description: Room temperature fluid
Study NCT01629511 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo stem cell transplant
Study NCT01629511 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: Given IV
Study NCT01629511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV
Study NCT01629511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Given IV
Study NCT04522271 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistant Starch
Description: 7.5 g resistant starch/m2 oral consumption
Study NCT04522271 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral consumption of food-grade cornstarch
Study NCT01683331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin treatment for hyperglycemia
Study NCT03715816 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Work break schedule
Description: Participants will receive 2.5-min breaks during a 90-min simulated laparoscopic surgery in the laboratory. The breaks will be either passive (simple rest) or active (selected mobilization exercises).
Study NCT01629511 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC
Study NCT01629511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV
Study NCT01629511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV
Study NCT01629511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given PO
Study NCT03194295 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Support Intervention Group
Description: This 12-week community support intervention is designed to activate and harness the powerful influences of drug-free family and friends to enhance recovery support and participation in community activities. Addiction Treatment Services (ATS) participants and their CSPs will be directed to participate in recovery-oriented community activities together 2 times per week and work together toward developing regular drug-free social support for the ATS participant. The group provides an opportunity for both the participant and CSP to discuss their experiences participating in the scheduled activities. For those electing not to engage in community activities, problem-solving strategies will be used to remove obstacles to participation, with other group members providing support and encouragement.
Study NCT03194295 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Substance Use Disorder Educational Group
Description: This 12-week educational group is designed as an attention-control group. Group topics include: 1) definition of substance dependence, 2) the disease model, 3) medical aspects, 4) mood, 5) personality, 6) self-esteem, 7) relapse prevention, 8) HIV/AIDS, 9) anger, 10) negative thinking, 11) nutrition, and 12) assertiveness. Participants will be assigned 2 homework assignments each week based on the topic.
Study NCT00560573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-751,871
Description: CP-751,871 at doses ranging from 6 to 20 mg/Kg on Day 1 of each 21-day cycle. CP-751,871 may be administered even after active comparators discontinuation, for a total number of 17 cycles (1 year).
Study NCT03613207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oraqix® gel
Description: Oraqix® gel (2.5% lidocaine, 2.5% prilocaine, Dentsply Pharmaceutical Inc., US/Dentsply DETRY GmbH, Germany) will be applied to 1 test site per subject
Study NCT00729937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: 500 mg, four times per day.
Study NCT00729937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin
Description: 300 mg, four times per day.
Study NCT00729937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet administered orally.
Study NCT00729937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Description: 4 single strength Trimethoprim/Sulfamethoxazole (TMP/SMX), 80 mg/400 mg each, twice per day.
Study NCT03613207 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dOFM-System
Description: Dermal open flow microperfusion system will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentrations over 24 hours
Study NCT03613207 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: 8 blood samples will be collected in order to assess systemic lidocaine/prilocaine concentrations pre-dose (1 sample) and 24 hours post dose (7 samples)
Study NCT03112161 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eucaloric Feeding Period
Study NCT03112161 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Overfeeding Feeding Period
Study NCT03112161 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Underfeeding Feeding Period
Study NCT01026870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SCH 32088 mometasone furoate (MF) metered-dose inhaler
Description: 2 inhalations from a MF 50 mcg inhaler each morning and evening, approximately 12 hours apart, for 12 weeks.
Study NCT01026870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo metered-dose inhaler BID
Description: 2 inhalations from a placebo metered-dose inhaler each morning and evening, approximately 12 hours apart, for 12 weeks.
Study NCT02034526 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: DDDR-60
Description: DDDR, lower pacing rate 60 bpm, RR activated (low-moderate)
Study NCT02034526 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DDD-40
Description: DDD, lower pacing rate 40 bpm, RR function off
Study NCT01818804 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: n-3PUFA
Study NCT01818804 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: olive oil
Study NCT04070833 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Dietary Supplement: Vitamin D-3 (cholecalciferol), 2000 IU Other Name: cholecalciferol
Study NCT04070833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil
Description: Drug: Omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])
Study NCT04070833 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D placebo
Description: Vitamin D placebo